Zobrazeno 1 - 10
of 151
pro vyhledávání: ''
Autor:
Waleed S. Al Amri, William E. Hughes, James L. Thorne, Geoff Wells, Ian M. Carr, Brian V Hogan, Thomas A. Hughes, Fiona Langlands, Arindam Pramanik, Layla K. Younis, Stacey J. Jones, Sarah A. Harris, Eldo T. Verghese, Rebecca Millican-Slater, Nevine M.F. El Deeb, Mervat A. Hamza, Baek Kim, Noha Gwili
Publikováno v:
British Journal of Cancer
Background Breast cancer stem cells (BCSCs) are drivers of therapy-resistance, therefore are responsible for poor survival. Molecular signatures of BCSCs from primary cancers remain undefined. Here, we identify the consistent transcriptome of primary
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99a64defdd7881cec05092b3963a5ac9
https://eprints.whiterose.ac.uk/174958/7/s41416-021-01484-w.pdf
https://eprints.whiterose.ac.uk/174958/7/s41416-021-01484-w.pdf
Autor:
James L. Thorne, Melina C. Teske, Robyn V. Broad, Andrew M. Hanby, Laura M. Wastall, Stacey J. Jones, Thomas A. Hughes
Publikováno v:
British Journal of Cancer
Background Triple negative breast cancers (TNBC) have poor prognoses despite aggressive treatment with cytotoxic chemotherapy. Cancer-associated fibroblasts (CAFs) are prominent in tumour stroma. Our hypothesis was that CAFs modulate chemotherapy sen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::027115557c95f3f47f1ecb119dec9f3d
Autor:
Elise Klæstad, Signe Opdahl, Monica J. Engstrøm, Elisabeth Wik, Borgny Ytterhus, Anna M. Bofin, Marit Valla
Publikováno v:
Breast Cancer Research and Treatment
Purpose MRPS23 is recognized as a driver of proliferation in luminal breast cancer. The aims of the present study were to describe MRPS23 copy number change in breast cancer, and to assess associations between MRPS23 copy number change and molecular
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49102c4df90ac263d4c308ee2094e138
https://hdl.handle.net/11250/2672584
https://hdl.handle.net/11250/2672584
Autor:
Miguel Gil-Gil, José A. García-Sáenz, E Dalmau Portulas, Elena García-Martínez, Nuria Ribelles, A. Santaballa Bertran, E. Martínez de Dueñas, I Alvarez-Lopez, Susana Bezares
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
Clinical & Translational Oncology
Universidad de Barcelona
Clinical & Translational Oncology
PurposeHormone receptor (HR)-positive, Human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) requires a therapeutic approach that takes into account multiple factors, with treatment being based on anti-estrogen hormo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b63a263cb82f360402dddafab187eefb
http://hdl.handle.net/2445/174389
http://hdl.handle.net/2445/174389
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
instname
[Background] Current therapeutic strategies that are used to combat breast cancer vary widely and largely depend on its clinicopathological features, including tumor subtype, size, stage, lymph node involvement, the presence of hormone receptors and/
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff6f37dcbb5ea82449e8289a41c8b7ba
http://hdl.handle.net/10261/201673
http://hdl.handle.net/10261/201673
Autor:
Arja Jukkola-Vuorinen, Anniina Jääskeläinen, Kirsi-Maria Haapasaari, Päivi Auvinen, Ylermi Soini, Peeter Karihtala
Publikováno v:
BMC Cancer
BMC Cancer, Vol 18, Iss 1, Pp 1-10 (2018)
BMC Cancer, Vol 18, Iss 1, Pp 1-10 (2018)
Background: The subtype of claudin-low breast cancer can be reliably determined only by gene-expression profiling. Attempts have been made to develop immunohistochemical surrogates, which nearly always focus on membranous claudin expression. Methods:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0882fc6ea4b5d717997d116945eea4b4
http://urn.fi/urn:nbn:fi-fe201804196713
http://urn.fi/urn:nbn:fi-fe201804196713
Autor:
Liisa M. Pelttari, Paula Poikonen-Saksela, Kristiina Aittomäki, Päivi Auvinen, Arja Jukkola-Vuorinen, Sanna Hallamies, Heli Nevanlinna, Johanna Mattson, Carl Blomqvist, Antti Jekunen
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-5 (2017)
BMC Cancer
BMC Cancer
Background Several susceptibility genes have been established for female breast cancer, of which mutations in BRCA1 and especially in BRCA2 are also known risk factors for male breast cancer (MBC). The role of other breast cancer genes in MBC is less
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4819e7805611ab5361165ecad3b1625
https://erepo.uef.fi/handle/123456789/5171
https://erepo.uef.fi/handle/123456789/5171
Publikováno v:
Breast Cancer Research : BCR
We read with interest the recent article by Roth and colleagues [1] reporting the findings of altered tumorspecific microRNAs (miRNAs) in sera of breast cancer patients. This report further substantiates emerging data suggesting that blood-based miRN
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e37de41d6ad927b9cb6665402fe5e878
http://hdl.handle.net/10379/11894
http://hdl.handle.net/10379/11894
Autor:
C. Rose, R Leonard, M Tubiana-Hulin, Denis Lacombe, J Vinholes, J Wildiers, J Michel, Robert E. Coleman, J Nortier, J. Ford, F. Mignolet, P Bastit
Publikováno v:
British Journal of Cancer
This study was designed to evaluate new bone resorption and tumour markers as possible alternatives to serial plain radiographs for the assessment of response to treatment. Thirty-seven patients with newly diagnosed bone metastases from breast cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76f16dd46c0774b038d4bedfedc3bf7f
Autor:
Andrzej Sygut, Julia Kruk-Jeromin, Ireneusz Majsterek, Adam Dziki, Grażyna Pasz-Walczak, Jan Rykała, Karolina Przybyłowska
Publikováno v:
Pathology Oncology Research
Tumoural angiogenesis is essential for the growth and spread of breast cancer cells. Therefore the aim of this study was to assess the diagnostic performance of angiogenesis markers in tumours and there reflecting levels in serum of breast cancer pat